FIGURE 2.

Once‐weekly exenatide (EQW) effects on renal disease progression, as a function of other risk factors. A, EQW effect on estimated glomerular filtration rate (eGFR) slope, as a function of other risk factors at baseline. B, EQW effect on percent change in urinary albumin:creatinine ratio (UACR), as a function of other risk factors at baseline. Renin‐angiotensin‐aldosterone system inhibitors (RAASi) include angiotensin‐converting enzyme inhibitors, angiotensin‐receptor blockers and direct renin inhibitors. BMI, body mass index; CV, cardiovascular; SBP, systolic blood pressure